Preview

FARMAKOEKONOMIKA. Modern Pharmacoeconomic and Pharmacoepidemiology

Advanced search

Search


Order results by:     
 
Issue Title
 
Vol 12, No 2 (2019) Pharmacoeconomic analysis of ceftazidime+avibactam (Zavicefta®) in the treatment of sepsis caused by carbapenem-resistant enterobacteria Abstract  similar documents
S. V. Nedogoda, A. S. Salasyuk, I. N. Barykina, V. O. Smirnova
"... with ceftazidime + avibactam amounted to 228.3 thousand rubles, which was lower than the cost of using ..."
 
Vol 11, No 1 (2018) Presepsin as a sepsis biomarker Abstract  similar documents
K. A. Trunova
"... The aim of this review is to analyze the usefulness of the diagnostic sepsis marker – presepsin ..."
 
Vol 9, No 1 (2016) SYSTEMATIC REVIEW OF PENTAGLOBIN EFFICACY IN PREVENTING MORTALITY IN NEWBORNS AND OLDER CHILDREN WITH BACTERIAL INFECTIONS AND SEPSIS Abstract  similar documents
V. K. Fedyaeva, O. Yu. Rebrova
"... mortality in newborns and older children with bacterial infections and sepsis. The aim of the study ..."
 
Vol 11, No 2 (2018) Pharmacoeconomic analysis of treatment with nilotinib as the second line therapy in patients with chronic myeloid leukemia Abstract  similar documents
N. A. Avxentyev, M. Yu. Frolov, A. S. Makarov
"... approval process. Results. The average medical cost (per year) for nilotinib (1 683 thousand rubles or US ..."
 
Vol 9, No 2 (2016) METASTATIC COLORECTAL TREATMENT COSTS OF USING TARGETED DRUGS IN SECOND AND FURTHER LINES THERAPY Abstract  similar documents
N. A. Avxentyev, E. V. Derkach, E. A. Pyadushkina, M. D. Ter-Ovanesov
"... per patient medication costs of using regorafenib are 255,000 rubles, which is 104,000 rubles less ..."
 
Vol 9, No 1 (2016) COST-EFFECTIVENESS ANALYSIS OF BRENTUXIMAB VEDOTIN IN ADULTS WITH RELAPSED OR REFRACTORY HODGKIN’S LYMPHOMA Abstract  similar documents
G. R. Khachatryan, D. V. Fedyaev, M. V. Avxentyeva, V. S. Dombrovskiy
"... of life for BV in patients with relapsed or refractory CD30-positive HL after ASCT was 524 thousand rub ..."
 
Vol 9, No 2 (2016) PHARMACOECONOMIC ANALYSIS OF VESOMNI (SOLIFENACIN AND CONTROLLED RELEASE TAMSULOSIN) TREATMENT OF STORAGE SYMPTOMS ASSOCIATED WITH BENIGN PROSTATIC HYPERPLASIA Abstract  similar documents
N. A. Avxentyev, M. Yu. Frolov
"... combined drug is cost saving alternative that annually requires 22,000 rubles per patient, which is 2 ..."
 
Vol 12, No 1 (2019) Prevalence survey of musculoskeletal and connective tissue disorders in the Russian Federation Abstract  similar documents
T. A. Oleynikova, D. N. Pozhidaeva, A. Yu. Oreshko
"... to the prognostic models, the prevalence of musculoskeletal diseases per 100 thousand population in the Russian ..."
 
Vol 8, No 1 (2015) PHARMACOECONOMIC ANALYSIS OF EVEROLIMUS IMMUNOSUPRESSIVE THERAPY AFTER RENAL TRANSPLANTATION Abstract  similar documents
M. V. Avxentyeva, N. A. Avxentyev, M. Yu. Frolov, E. V. Derkach
"... thousands (17%) per patient in a two-year period. The reduction mainly results from cheaper medication ..."
 
Vol 6, No 4 (2013) Pharmacoeconomic study of nutrition support in the conditions of current health care system in Russia Abstract  similar documents
I. A. Metelkin, R. I. Yagudina
"... and medical division) and late complications (pneumonia, sepsis, catheter and wound infection) treatment ..."
 
Vol 8, No 2 (2015) PHARMACOECONOMIC STUDIES TREATMENT OF PATIENTS WITH INJURIES IN THE DEPARTMENT OF ANESTHESIOLOGY AND RESUSCITATION WITH METHODS ANALYSIS THE COST OF ILLNESS Abstract  similar documents
Anton Alexandrovich Kasatkin
"... with the severity of the injury 31 points and made 11 000 and 5600 rubles. respectively. The cost of treating ..."
 
Vol 8, No 4 (2015) PHARMACOECONOMIC EVALUATION OF INFLUENZA AND PNEUMOCOCCAL VACCINATION IN EMPLOYEES OF THE JOINT STOCK COMPANY "RUSSIAN RAILWAYS" (JSCO "RZD") ON INVESTMENT FOR THE EMPLOYER Abstract  similar documents
D. A. Zhukov
"... .9 billion rubles (42.2 million EUR). According to the generated modelling, the pneumococcal (PPSV23 ..."
 
Vol 8, No 4 (2015) THE COST OF NUTRITION ALTERNATIVES FOR PREMATURE INFANTS IN RUSSIA Abstract  similar documents
K. V. Gerasimova, M. V. Avxentyeva, I. A. Belyaeva
"... .14 rubles, respectively). The cost per averted case of NE was 21 115 rubles within 35 days that is less than ..."
 
Vol 8, No 2 (2015) CLINICAL AND ECONOMIC ANALYSIS OF THE USE OF DIFFERENT TYPES OF SYSTEMS OF VENOUS ACCESS IN THE TREATMENT OF CHILDREN WITH CANCER Abstract  similar documents
Maksim Yur'evich Rykov, Vladimir Georgievich Polyakov
"... of treatment five subclavian catheters necessary to spend 227.25 mln. rubles. And the implantations of venous ..."
 
Vol 7, No 3 (2014) ASSESSMENT OF NECESSARY FINANCIAL EXPENSES ON THE DRUG SUPPLY OF THE PATIENTS WITH ORPHAN DISEASES IN THE RUSSIAN FEDERATION Abstract  similar documents
M. V. Sura, K. V. Gerasimova, V. V. Omelyanovskiy, M. V. Avksentyeva
"... orphan diseases were 15.73 bln rubles per year (6.36 bln rubles for children and 9.37 bln rubles ..."
 
Vol 10, No 1 (2017) EVALUATION OF DRUG THERAPY IN PROGRESSING DIFFERENTIATED THYROID CANCER REFRACTORY TO RADIOACTIVE IODINE IN PATIENTS RESIDING IN THE RUSSIAN FEDERATION : PHARMACOECONOMIC ASPECTS Abstract  similar documents
M. Yu. Frolov, V. A. Rogov
"... with sorafenib or lenvatinib was 7 285 716.92 rubles or 3 368 077.62 rubles, respectively. ..."
 
Vol 8, No 1 (2015) SOCIAL AND ECONOMIC BURDEN OF FIVE NATURAL FOCAL INFECTIONS IN THE RUSSIAN FEDERATION Abstract  similar documents
A. E. Platonov, N. A. Avksentyev, M. V. Avksentyeva, E. V. Derkach, O. V. Platonova, A. V. Titkov, N. M. Kolyasnikova
"... with vector-borne infectious diseases comprised 909 million rubles in prices of 2011; most of the value ..."
 
Vol 7, No 3 (2014) PHARMACOECONOMIC ANALYSIS OF THE USE OF OXALIPLATIN CHEMOTHERAPY FOR COLORECTAL CANCER.REAL (ACTUAL) CLINICAL PRACTICE DATA Abstract  similar documents
A. V. Pavlysh, A. S. Kolbin, A. R. Kasimova
"... .2%. Middle cover price of case report was 252,294 rubles. In average oxaliplatin therapy was effective in 83 ..."
 
Vol 8, No 4 (2015) HEALTHCARE SPENDING EFFICIENCY IN RUSSIAN REGIONS Abstract  similar documents
N. A. Avxentyev, V. M. Baydin, O. A. Zarubina, N. N. Sisigina, S. A. Kulkova
"... healthcare spending inefficient, which equals to real 269-435 billion rubles of inefficient spending annually.  ..."
 
Vol 7, No 2 (2014) EPIDEMIOLOGIC RESEARCH ON EPILEPSY IN MINSK Abstract  similar documents
T. V. Dokukina, T. S. Golubeva, I. V. Matveichuk, M. V. Mahrov, V. M. Loseva, E. V. Krupenkina, S. A. Marchuk
"... эпилепсией в районе составляла от 165,2 на 100 тыс. населения в 2008 г., до 275,5 – на 100 тыс. населения в ..."
 
Vol 9, No 1 (2016) PHARMACOECONOMIC STUDY OF LENVIMA (LENVATINIB) IN ADVANCED PROGRESSIVE RADIO IODINE REFRACTORY DIFFERENTIATED THYROID CANCER IN THE RUSSIAN FEDERATION Abstract  similar documents
M. Yu. Frolov, V. A. Rogov
"... at the same time constitute 5 213 900 000 rub. (670.5 to 1184.3 million rubles per year). Calculated unit ..."
 
Vol 8, No 4 (2015) CLINICAL AND ECONOMIC EVALUATION OF THROMBOPOIETIN RECEPTOR AGONISTS IN THE TREATMENT OF CHRONIC IDIOPATHIC THROMBOCYTOPENIC PURPURA IN ADULTS Abstract  similar documents
E. A. Pyadushkina, M. Yu. Frolov, M. V. Avksentyeva
"... of one patient annual therapy by 2.68 mln. rubles. Budget impact analysis evidences that Eltrombopag ..."
 
Vol 5, No 2 (2012) COST EFFECTIVENESS OF ORAL PERICALCITOL IN PATIENTS WITH STAGE III-IV CHRONIC KIDNEY DISEASE AND SECONDARY HYPERPARATHYREOSIS Abstract  similar documents
A. V. Rudakova
"... ,4 тыс. руб. на 1 дополнительный год без диализа (381,3 тыс. руб./ 1 дополнительный год без диализа с ..."
 
Vol 9, No 3 (2016) CLINICAL AND ECONOMIC EVALUATION OF LACOSAMIDE IN PATIENTS WITH PARTIAL EPILEPSY Abstract  similar documents
E. A. Pyadushkina, M. Yu. Frolov
"... .64, 2.65, 4.74 million rubles in the first, second and third year respectively. Scenario 3 ..."
 
Vol 10, No 3 (2017) Evaluation of economic damage from multiple sclerosis in the city of Ufa, Russia Abstract  similar documents
E. V. Ivanova, K. Z. Bachtiyarova
"... 428,222,026.35 rubles per year, mostly due to direct medical costs; of those, almost 50% is spent ..."
 
Vol 12, No 2 (2019) Comparative modeling of socio-economic burden among smokers, nonsmokers and former smokers Abstract  similar documents
E. V. Radchenko, A. S. Kolbin
"... disability) was 510.6 billion rubles. The difference between the smokers and the equal-sized non-smoking ..."
 
Vol 5, No 3 (2012) CLINICAL AND ECONOMIC BENEFITS OF HUMAN INSULIN ANALOGUESUSE Abstract  similar documents
E. E. Arinina, M. A. Rashyd
"... ®) were 21774 rubles per patient/year, while the cost of an averted severe hypoglycemia was 24728 rubles ..."
 
Vol 11, No 3 (2018) Pharmacoeconomic analysis of using belimumab for the treatment of systemic lupus erythematosus Abstract  similar documents
A. G. Tolkushin, N. L. Pogudina
"... in patient survival. The total costs for belimumab vs standard therapy approximated 8.84 million rubles vs 17 ..."
 
Vol 8, No 2 (2015) ASSESSMENT OF ECONOMIC EFFICIENCY OF APPLICATION OF RALTEGRAVIR BY PATIENTS WITHOUT EXPERIENCE OF TYPE 1 HIV INFECTION THERAPY IN RUSSIA Abstract  similar documents
Elamin H. Elbasha, Elena Aleksandrovna Pyadushkina, Maria Vladimirovna Avxentyeva, Alexander Gennadievich Tolkushin, Maxim Yurievich Frolov
"... ) per a year of saved life with consideration of its quality comprised 1,097,078 rubles without ..."
 
Vol 9, No 3 (2016) METHOD «COST-EFFECTIVENESS» IN EVALUETION OF ATIBIOTIC TREATMENT OF ACYTR OBSTRUCTIVE BRONCHITIS IN CHILDREN IN HOSPITAL Abstract  similar documents
O. V. Zhukova, S. V. Kononova
"... for Sumamed (Teva), and it amounted to 39 367.50 rubles. Sumamed was characterized by the highest clinical ..."
 
Vol 11, No 2 (2018) Clinical and economic efficiency of the loop ileostomy closure by various methods Abstract  similar documents
A. V. Veselov, S. I. Achkasov, O. I. Sushkov, A. I. Moskalev, I. S. Lantsov
"... ,704.90 rubles. and 145,473.70 rubles, respectively, while in group 3, the cost was higher – 167,443,60 rubles (p ..."
 
Vol 11, No 3 (2018) Determination of a willingness-to-pay threshold and decision-making in financing the healthcare technologies Abstract  similar documents
T. S. Teptsova, T. P. Bezdenezhnyh, V. K. Fedyaeva, N. Z Musina, G. R. Hachatryan, V. V. Tarasov
"... ,878.21 rubles, and the cost of one additionally saved QALY – 365,060.31 rubles. Conclusion. The WTPT ..."
 
Vol 7, No 1 (2014) CLINICAL AND PHARMACOECONOMIC ANALYSIS OF CARBAPENEMS (MEROPENEM, IMIPENEM AND DORIPENEM) IN NOSOCOMIAL PNEUMONIA TREATMENT Abstract  similar documents
I. I. Shteynberg, S. K. Zyryanov, Yu. B. Belousov
"... около 30 тыс. рублей [2]. По дан- ным, полученным в США и странах Европы, затраты, связанные с эпизодом ..."
 
Vol 7, No 3 (2014) MODELI NG CLINICAL AND ECONOMIC OUTCOMES OF TESTING FOR LTBI WITH T-SPOT.TB IN IMMUNOCOMPROMISED CHILDREN Abstract  similar documents
V. I. Ignatyeva, M. V. Avxentyeva, V. V. Omelyanovsky, G. R. Khachatryan
"... тестирование – 7,9 тыс. руб.) и 1,07 млн руб. при использовании T-SPOT.TB (в т.ч. затраты на тестирование – 250 ..."
 
Vol 5, No 3 (2012) PHARMACOECONOMIC EVALUATION OF TREATMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS ON DIALYSIS WITH CINACALCET Abstract  similar documents
R. I. Yagudina, V. G. Serpik
"... was 20,709 rubles. (Taking into account the costs of dialysis treatments), and for standard therapy - 110 ..."
 
Vol 8, No 4 (2015) ABC-, VEN- AND FREQUENCY ANALYSIS OF TREATMENT OF ATRIAL FIBRILLATION IN OUTCOME PATIENTS Abstract  similar documents
A. N. Korobeynikova, S. V. Malchikova
"... . For the treatment of patient with atrial fibrillation it spends an average of 11245.2 rubles per patient ..."
 
Vol 11, No 1 (2018) Antimicrobial therapy of community-acquired pneumonia in a hospital setting (clinical and economic aspects) Abstract  similar documents
O. V. Zhukova, O. V. Ruina, M. V. Khazov, S. V. Romanov
"... of moderate CAP were: 10.5 days and 731.65 rubles for ceftriaxone;  9.1 days and 1353.00 rubles ..."
 
Vol 10, No 3 (2017) Initiation and intensification of insulin therapy in patients with type 2 diabetes mellitus: a budget impact analysis Abstract  similar documents
E. V. Biryukova, V. I. Ignat’eva
"... insulin for the model population of 1,000 patients was 22.5 million rubles. If the use of ready-made ..."
 
Vol 10, No 1 (2017) BIOLOGICAL THERAPY IN ADULT PATIENTS WITH ULCERATIVE COLITIS AND CROHN’S DISEASE: BUDGET IMPACT ANALYSIS Abstract  similar documents
E. A. Pyadushkina
"... % and 7% for the first, second and third year is expected to result in cost savings of 26.4 million rubles ..."
 
Vol 8, No 4 (2015) PLANNING OF EXTENT AND FINANCIAL EXPENSES FOR DELIVERY OF HEALTH CARE IN HOSPITALS AT THE FEDERAL AND REGIONAL LEVELS Abstract  similar documents
M. V. Sura
"... per year; the norm of financial expenses was 63 743,8 rubles and 22 233,1 rubles per one case ..."
 
Vol 12, No 1 (2019) Economic consequences of healthcare optimization for IBD patients in the Republic of Tatarstan Abstract  similar documents
T. P. Bezdenezhnykh, D. V. Fedyaev, G. R. Khachatryan, G. G. Arutyunov, K. V. Gerasimova
"... by 120 million rubles over 5 years. The sensitivity analysis shows the results are robust ..."
 
Vol 5, No 2 (2012) MEDICO-ECONOMIC SUBSTANTIATION OF NORMATIVE STANDARD OF SUPPLYING STUDENTS OF MILITARY SCHOOLS WITH MEDICATIONS Abstract  similar documents
Yu. V. Miroshnichenko, V. S. Gaynov
"... 19 училищ, насчитывающих порядка 10,5 тыс. обучающихся. К 2013 году ко- личество училищ будет ..."
 
Vol 9, No 2 (2016) GENDER FEATURES OF THE POPULATION'S ATTITUDE TO MEDICINES Abstract  similar documents
N. B. Dremova, N. P. Yaroshenko, N. I. Afanaseva, S. V. Solomka
"... браке 64,7 49,3 57,0 6.2 не в браке 35,3 50,7 43,0 7 Средний доход в семье на 1 чел. 7.1 до 6 тыс. руб ..."
 
Vol 6, No 4 (2013) Pharmacoeconomical analysis of use of the low-molecular weight heparins for prevention of the venous tromboembolism in the conditions of multidisciplinary hospital Abstract  similar documents
A. S. Kolbin, I. A. Vilyum, M. A. Proskurin, Yu. E. Balykina
"... соответствии с международными рекомендациями 2012 г. у больных с тяжелым сепсисом и септи- ческим шоком, с ..."
 
Vol 5, No 1 (2012) PHA RMA COE CONOMI CAL EVALUATION OF MULTIPLE MYELOMA TREATMENT WITH REVLIMID (LENALIDOMIDE ) IN THE RUSSIAN FEDE RATION Abstract  similar documents
R. Yagudina, A. Kulikov, B. Misikova
"... Европе было выявлено 15 тыс. случаев ММ у мужчин и 13,7 тыс. у женщин. Об- щая распространенность ..."
 
Vol 7, No 2 (2014) ANALYSIS OF DRUG PRODUCTS ASSORTMENT ACQUIRABLE BY HEALTHCARE ORGANIZATIONS FOR MEDICAL TREATMENT IN HOSPITAL SETTINGS WAS CONDUCTED Abstract  similar documents
M. G. Malaev
"... лекарственных средств В соответствии с контрактами, заключенными на общую сумму 1 493 484,2 тыс. руб., в ..."
 
Vol 5, No 1 (2012) VI CONGRESS WITH INTERNATIONAL PARTICIPATION «DEVELOPMENT OF PHARMACOECONOMICS AND PHARMACOEPIDEMIOLOGY IN RUSSIAN FEDERATION» Abstract  similar documents
"... на 30%. Стоимость лечения одного больного, перенесшего инсульт, составляет 127 тыс. рублей в год. Эти ..."
 
Vol 8, No 2 (2015) REASONS FOR DIFFICULTY OF THE PHARMACOECONOMIC ANALYSIS FOR ORPHAN DRUGS. WAYS FOR SOLUTIONS Abstract  similar documents
Andrey Vladislavovich Pavlysh, Aleksei Sergeevich Kolbin, Roman Andreevich Gapeshin, Stanislav Mikhailovich Malyshev
"... случаев на 100 тыс. населения [4]. По состоянию на 2014 г. в Российской Федерации (РФ) в Федеральный ..."
 
1 - 50 of 73 Items 1 2 > >> 

Search tips:

  • Search terms are case-insensitive
  • Common words are ignored
  • By default articles containing any term in the query are returned (i.e., OR is implied)
  • Make sure that a word exists in an article by prefixing it with +; e.g., +journal +access scholarly academic
  • Combine multiple words with AND to find articles containing all terms; e.g., education AND research
  • Exclude a word by prefixing it with - or NOT; e.g., online -politics or online NOT politics
  • Search for an exact phrase by putting it in quotes; e.g., "open access publishing". Hint: Quoting Chinese or Japanese words will help you to find exact word matches in mixed-language fields, e.g. "中国".
  • Use parentheses to create more complex queries; e.g., archive ((journal AND conference) NOT theses)